Healthcare / Drug Manufacturers - GeneralXETRA
$182.90
-3.25 (-1.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $17.8B · quality 84.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$323.1B
P/E
104.5x
↑EV/EBITDA
21.9x
↑ROE
-129.2%
↓Gross Margin
70.2%
↑Debt/Equity
-20.64
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.8%
FCF CAGR
-9.8%
FCF margin
29.1%
FCF / Net income
4.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $61.16B · net income $4.23B · FCF $17.82B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $61.16B | $61.16B | $56.33B | $54.32B | $58.05B |
| Net Income | $4.23B | $4.23B | $4.28B | $4.86B | $11.84B |
| EBITDA | $17.63B | $17.63B | $14.91B | $17.17B | $24.17B |
| EPS | 2.37 | 2.37 | 2.39 | 2.72 | 6.63 |
| Gross Margin | 70.2% | 70.2% | 70.0% | 62.4% | 70.0% |
| Operating Margin | 32.8% | 32.8% | 21.1% | 24.9% | 32.4% |
| Net Margin | 6.9% | 6.9% | 7.6% | 9.0% | 20.4% |
| Balance Sheet | |||||
| Debt/Equity | -20.64 | -20.64 | 20.19 | 5.73 | 3.67 |
| Current Ratio | 0.80 | 0.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $17.82B | $17.82B | $17.83B | $22.06B | $24.25B |
| Returns | |||||
| ROE | -129.2% | -129.2% | 128.7% | 46.9% | 68.6% |
| Valuation | |||||
| P/E | 104.51 | 104.51 | 73.34 | 54.52 | 23.86 |
| EV/EBITDA | 21.93 | 21.93 | 24.98 | 18.02 | 13.87 |
| P/B | — | — | 93.47 | 25.38 | 16.30 |
| Growth & Yield | |||||
| Revenue Growth | 8.6% | 8.6% | 3.7% | -6.4% | — |
| EPS Growth | -0.8% | -0.8% | -12.1% | -59.0% | — |
| Dividend Yield | 3.2% | 3.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
89.9%
EPS terminal req.
$16.23
Spread vs growth
-90.7%
5Y implied EPS CAGR
52.6%
EPS terminal req.
$19.64
Spread vs growth
-53.5%
10Y implied EPS CAGR
29.6%
EPS terminal req.
$31.63
Spread vs growth
-30.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.2%
Start / end P/E
69.0x → 77.2x
EPS bridge
2.39 → 2.37
Residual
-0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.